A protocol for a multicentre, randomised, double-blind, placebo-controlled trial to compare the effect of annual infusions of zoledronic acid to placebo on knee structural change and knee pain over 24 months in knee osteoarthritis patients – ZAP2

BACKGROUND: Bisphosphonates are a class of drugs that slow bone loss and are a promising candidate to treat knee osteoarthritis (OA) patients. In a pilot study, we demonstrated that zoledronic acid reduced knee pain and size of subchondral bone marrow lesions (BMLs) over 6 months in knee OA patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Aitken, Dawn, Laslett, Laura L., Cai, Guoqi, Hill, Catherine, March, Lyn, Wluka, Anita E., Wang, Yuanyuan, Blizzard, Leigh, Cicuttini, Flavia, Jones, Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052532/
https://www.ncbi.nlm.nih.gov/pubmed/30021646
http://dx.doi.org/10.1186/s12891-018-2143-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052532/
https://www.ncbi.nlm.nih.gov/pubmed/30021646
http://dx.doi.org/10.1186/s12891-018-2143-2

Ejemplares similares